Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy
- Conditions
- Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 114
- Registration Number
- NCT01972724
Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.
- Conditions
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 41
- Registration Number
- NCT01971034
- Locations
- 🇧🇷
ICESP, Sao Paulo, SP, Brazil
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 157
- Registration Number
- NCT01966978
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Effect of Insulin Sensitizer Metformin on AD Biomarkers
- Conditions
- Alzheimer's DiseaseVascular DementiaDementiaMemory Impairment
- Interventions
- Drug: MetforminDrug: Placebos
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 20
- Registration Number
- NCT01965756
- Locations
- 🇺🇸
University of Pennsylvania, Penn Memory Center, Philadelphia, Pennsylvania, United States
Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 84
- Registration Number
- NCT01963663
- Locations
- 🇮🇷
Diabetes Clinic, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Bayer
- Registration Number
- NCT01961388
Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity
- Conditions
- Prediabetes
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01960205
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 461
- Registration Number
- NCT01958671
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 48
- Registration Number
- NCT01956305
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
- Conditions
- Prediabetic StateInsulin Resistance
- Interventions
- Drug: PlaceboDrug: Metformin
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT01956929
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.